Wedelolactone

Overview

Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase ( 5-Lox ) with an IC 50 of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt . Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer .

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Lipoxygenase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-N0551
• CAS No.: 524-12-9
• Molecular Formula: C16H10O7
• Molecular Weight: 314.25
• Purity: 99.87%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution
• Availability: In-stock

Source

Original product source